BMY Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 22:00):

Stats
Tagesvolumen	14.08M
Durchschnittsvolumen	15.91M
Marktkapitalisierung	88.58B
EPS	$0 ( 2024-04-25 )
Nächstes Ertragsdatum	( $1.680 ) 2024-07-25
Last Dividend	$0.600 ( 2024-01-04 )
Next Dividend	$0 ( N/A )
P/E	-14.10
ATR14	$0.0340 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Shanahan Karin	Sell	3 306	Restricted Stock Units
2024-04-01	Shanahan Karin	Buy	3 306	Common Stock, $0.10 par value
2024-04-01	Shanahan Karin	Sell	1 196	Common Stock, $0.10 par value
2024-03-31	Yale Phyllis R	Buy	645	Deferred Share Units
2024-03-31	Storch Gerald L	Buy	691	Deferred Share Units

INSIDER POWER
31.44
Last 100 transactions
Buy: 432 337 \| Sell: 225 479

Volumen Korrelation

Lang: -0.60 (weak negative)

Kurz: -0.82 (strong negative)

Signal:(48.576) Neutral

Bristol-Myers Squibb Co Korrelation

10 Am meisten positiv korreliert
UVV	0.926
AJAX	0.919
PYN	0.908
BSM	0.897
HLGN	0.892
BAK	0.89
HKIB	0.888
STZ	0.888
SDCI	0.886
WE	0.884

10 Am meisten negativ korreliert
IRL	-0.903
PANA	-0.883
IVH	-0.878
GOGN	-0.878
GOTU	-0.872
MGU	-0.871
ESM-UN	-0.871
STAR-PI	-0.869
HWKZ	-0.868
SGU	-0.866

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Bristol-Myers Squibb Co Korrelation - Währung/Rohstoff

0.48
( neutral )

0.39
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.58
( weak )

-0.37
( neutral )

Bristol-Myers Squibb Co Finanzdaten

Annual	2023
Umsatz:	$45.01B
Bruttogewinn:	$34.31B (76.24 %)
EPS:	$3.88

FY	2023
Umsatz:	$45.01B
Bruttogewinn:	$34.31B (76.24 %)
EPS:	$3.88

FY	2022
Umsatz:	$46.16B
Bruttogewinn:	$36.02B (78.04 %)
EPS:	$2.97

FY	2021
Umsatz:	$46.39B
Bruttogewinn:	$36.45B (78.57 %)
EPS:	$3.25

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.540 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.600 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.65 - average (55.60%) | Divividend Growth Potential Score: 1.215 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00892	1972-07-26
Last Dividend	$0.600	2024-01-04
Next Dividend	$0	N/A
Payout Date	2024-02-01
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$44.07	--
Avg. Dividend % Per Year	2.48%	--
Score	4.52	--
Div. Sustainability Score	5.65
Div.Growth Potential Score	1.215
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-08-12)

$0.605 Estimate 60.24 %

Dividend Stability

0.96 Excellent

Dividend Score

4.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0178	0.95%
1973	$0.0482	2.36%
1974	$0.0452	3.25%
1975	$0.0491	3.23%
1976	$0.0536	2.60%
1977	$0.0655	3.24%
1978	$0.0725	3.64%
1979	$0.0856	4.04%
1980	$0.0714	3.31%
1981	$0.106	3.50%
1982	$0.121	3.85%
1983	$0.174	4.36%
1984	$0.190	3.71%
1985	$0.224	3.67%
1986	$0.214	2.74%
1987	$0.250	2.49%
1988	$0.519	5.04%
1989	$0.483	4.57%
1990	$0.521	3.84%
1991	$0.593	3.74%
1992	$0.492	2.34%
1993	$0.685	4.34%
1994	$0.871	6.37%
1995	$0.528	3.80%
1996	$0.893	4.38%
1997	$0.728	2.86%
1998	$0.557	1.24%
1999	$0.820	1.32%
2000	$0.932	1.52%
2001	$1.061	1.56%
2002	$1.400	2.75%
2003	$1.120	4.66%
2004	$0.840	2.86%
2005	$1.120	4.40%
2006	$1.120	4.82%
2007	$1.120	4.25%
2008	$1.550	5.93%
2009	$1.250	5.23%
2010	$0.960	3.75%
2011	$1.320	4.97%
2012	$1.360	3.88%
2013	$1.760	5.38%
2014	$1.450	2.77%
2015	$1.490	2.50%
2016	$1.140	1.70%
2017	$1.560	2.62%
2018	$1.600	2.61%
2019	$1.640	3.13%
2020	$2.29	3.62%
2021	$1.470	2.39%
2022	$2.16	3.49%
2023	$2.28	3.16%
2024	$0.600	1.14%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.135	1.500	-2.70	-4.05	[0 - 0.5]
returnOnAssetsTTM	-0.0621	1.200	-2.07	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.230	1.500	-3.67	-5.50	[0.1 - 1]
payoutRatioTTM	-0.774	-1.000	-7.74	7.74	[0 - 1]
currentRatioTTM	1.110	0.800	9.45	7.56	[1 - 3]
quickRatioTTM	0.919	0.800	9.30	7.44	[0.8 - 2.5]
cashRatioTTM	0.361	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.580	-1.500	0.338	-0.507	[0 - 0.6]
interestCoverageTTM	10.69	1.000	7.15	7.15	[3 - 30]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.18	2.00	6.91	10.00	[0 - 20]
debtEquityRatioTTM	3.48	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.757	1.000	0.715	0.715	[0.2 - 0.8]
operatingProfitMarginTTM	0.306	1.000	5.88	5.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.239	1.000	9.78	9.78	[0.2 - 2]
assetTurnoverTTM	0.460	0.800	-0.268	-0.214	[0.5 - 2]
Total Score				5.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-14.38	1.000	-1.553	0	[1 - 100]
returnOnEquityTTM	-0.230	2.50	-2.36	-5.50	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.18	2.00	7.94	10.00	[0 - 30]
dividendYielPercentageTTM	5.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
payoutRatioTTM	-0.774	1.500	-7.74	7.74	[0 - 1]
pegRatioTTM	-0.0362	1.500	-3.57	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.301	1.000	4.96	0	[0.1 - 0.5]
Total Score				1.215

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.